Thor Medical ASA: Disclosure of Large Shareholding

10.9.2026 10:14:54 CEST | Thor Medical ASA | Major shareholdings notification

Oslo, Norway, 10 September 2026: Reference is made to the stock exchange announcements by Thor Medical ASA (the "Company") on 3 September 2026 regarding the successful completion of a private placement of new shares to be issued by the Company (the "Private Placement") and a retail offering through Nordnet (the "Retail Offering").

Reference is also made to the share lending agreement entered into by and between the Company, its shareholder Scatec Innovation AS as share lender and Arctic Securities AS and ABG Sundal Collier ASA as managers (the "Managers"), to facilitate delivery-versus-payment settlement in the Private Placement and the Retail Offering (the "Share Lending Agreement").

Today, following registration of the share capital increases pertaining to the Private Placement and the Retail Offering, the Managers will redeliver 57,291,667 new shares in the Company to Scatec Innovation AS pursuant to the Share Lending Agreement.

Following the effectuation of the redelivery of 57,291,667 new shares in the Company and the delivery of 5,208,333 new shares allocated to Scatec Innovation AS in the Private Placement, Scatec Innovation AS' holding of shares in the Company will be 87,326,613, equivalent to approx. 20.67% of the issued share capital and votes. Consequently, Scatec Innovation AS will cross above the 10%, 15% and 20% thresholds pursuant to section 4-2 (1) and (3) of the Norwegian Securities Trading Act.

This announcement is published in accordance with section 4-2 of the Norwegian Securities Trading Act.

Contacts

Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988 05 724, mathias.reierth@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is a leading supplier of high-purity isotopes to the radiopharmaceutical industry. The Company's proprietary production platform combines advanced separation technology with industrial-scale manufacturing capacity to deliver a reliable, scalable and cost-efficient supply of alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical companies from early-stage development to commercialization enabling scale-up of next-generation targeted cancer therapies. Thor Medical's product portfolio includes lead-212 (Pb-212) and its precursor isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on naturally occurring thorium, Thor Medical's production process requires neither irradiation nor nuclear reactors, providing significant cost advantages while minimizing radioactive waste. Guided by its vision to become a world-leading enabler for targeted cancer therapies, Thor Medical is committed to improving millions of lives by powering the next generation of precision cancer treatment with high-purity isotopes. Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the ticker symbol TRMED. For more information, visit www.thormedical.com.

Attachments

- Download announcement as PDF.pdf